Abstract 408P
Background
25% of patients with metastatic colorectal cancer (mCRC) will have liver affection at diagnosis. Surgery for liver metastases has expanded in recent decades, leading to increased survival for patients with mCRC.
Methods
We carried out a retrospective analysis of 554 patients with mCRC treated at the Gregorio Marañón Hospital (Spain) between January 2010 and 2021. We analyzed the clinical and molecular characteristics of patients undergoing liver metastasis surgery as 1st metastasis surgery together with relapse patterns to progression.
Results
These 554 patients with mCRC identified, 171 underwent at least 2 metastases surgeries, achieving a media of survival from the 2nd surgery of 36,41 months. We identified 169 patients with liver metastasis surgery as 1st surgery. Most of them were men (63,91%). At the begining of the diagnosis, the majority had an ECOG 0-1 (90,5%). 46 patients (27,2%) were more than 70 years old. Regarding the location of the primary, 46 patients (27,2%) had them in the right colon and 120 in the left colon (71,0%). Regarding the biomakers, we indentified the following mutations: 68 mutated KRAS (40,2%), 5 mutates NRAS (2,9%), 9 mutated BRAF (5,3%), 13 mutated PI3K (7,6%), 1 HER2 amplification (0,5%) and 4 with IMS phenotype (2,3%). 71 patients combined resection and complementary ablative techniques. 43 patients had extrahepatic disease at the time of surgery (25,4%). Based on the frecuency of surgeries, after the metastasis surgery had progressed as follows: mainly hepatic (50,3%), pulmonary (24,8%), peritoneal (11,8%), lymph node (12%), bones (4,7%), cerebral (1,1%). Relapses were analyzed by different biomakers (mutated RAS, Triple WT, BRAF) without having significant differences in relapse patterns at the statistics.
Conclusions
Patients undergoing sequential metastasis surgery have a long survival, that is why is important to analyze patterns of relapse after surgery. There is no evidence of significant differences in the progression patterns according to the mutational status of the mCRC after liver metastasis surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HGUGM.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.